Given the minimal disability and absence of MS activity over the past 4 years, in April 2024 (i.e., 8 months after the last dose of ocrelizumab), the patient was switched as a de-risking strategy to the sphingosine 1-phosphate receptor modulator (i-mod) ponesimod. This evidence concerns the gene S1PR1 and myeloid sarcoma.